Form 4: Immunome CEO Boosts Stake with $500K Stock Purchase

Immunome Inc.'s President and CEO, Clay B. Siegall, acquired 25,450 shares of common stock for approximately $500,000, increasing his direct beneficial ownership.

Summary

• Clay B. Siegall, President and CEO, Director, and 10% Owner of Immunome Inc., purchased 25,450 shares of common stock.
• The transaction occurred on March 27, 2026, at a weighted average price of $19.67 per share.
• The total value of the acquisition was approximately $500,601.50 (25,450 shares * $19.67/share).
• Following this transaction, Siegall directly beneficially owns 690,704 shares of Immunome Inc. common stock.
• The purchase was made pursuant to a Rule 10b5-1 trading plan.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a strong positive signal, as a significant insider purchase by the CEO typically indicates high confidence in the company's future prospects and potential undervaluation of its stock.

Positives

• A significant insider purchase by the President and CEO, Director, and 10% Owner, Clay B. Siegall, signals strong confidence in Immunome Inc.'s future prospects.
• The acquisition of 25,450 shares at an average price of $19.67 represents a substantial personal investment of over $500,000.
• The transaction was executed under a Rule 10b5-1 plan, indicating a pre-planned investment strategy.

Future Outlook

This Form 4 filing does not contain explicit forward-looking statements or guidance, beyond the implicit confidence shown by the insider purchase.

Industry Context

StockSavvy.ai notes that insider purchases, especially by top executives like the CEO, are often interpreted by the market as a positive signal, suggesting management believes the company's stock is undervalued or expects significant positive developments. This is particularly relevant in the biotechnology sector (Immunome Inc. is a biotech company), where future pipeline success and regulatory approvals are key drivers of stock performance.

Comparison to Industry Standards

• Insider buying activity, particularly by a CEO, is generally viewed favorably across all industries, often outperforming general market sentiment.
• While specific comparable companies or projects are not detailed in this filing, a purchase of over $500,000 by a CEO is a substantial investment, indicating a high level of conviction, which is a strong signal compared to minor or routine insider transactions seen in other firms.

Related Party Transactions

• The purchase of 25,450 shares of common stock by Clay B. Siegall, the President and CEO, Director, and 10% Owner, constitutes a related party transaction.

Stakeholder Impact

• Shareholders: May view this as a positive signal, potentially increasing investor confidence and demand for the stock.
• Employees: Could interpret the CEO's investment as a sign of stability and belief in the company's long-term vision.

Key Dates

Recommendation

The significant insider purchase by the CEO, who also serves as a Director and 10% owner, signals strong conviction in Immunome Inc.'s future. Such a substantial personal investment, especially under a 10b5-1 plan, suggests management believes the stock is undervalued and anticipates positive developments. This action typically precedes periods of outperformance and is a compelling indicator for a "strong buy" recommendation.

Keywords

Immunome Inc., IMNM, Insider Trading, Stock Purchase, CEO, Director, Form 4, Clay B. Siegall, Equity Acquisition, 10b5-1 Plan